Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RAMM PharmaXCNQ:RAMM +100.00% Receivables Turnover is 1.96 as of Apr. 2026. The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, RAMM Pharma ranks worse than 64.11% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. RAMM Pharma's Revenue for the
three
months ended in Apr. 2026 was C$0.19 Mil. RAMM Pharma's average Accounts Receivable for the
three
months ended in Apr. 2026 was C$0.10 Mil.
Hence, RAMM Pharma's Receivables Turnover for the
three
months ended in Apr. 2026 was 1.96.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
RAMM Pharma Receivables Turnover Related Terms
RAMM Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:RAMM vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Receivables Turnover of 1.96 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RAMM Pharma and its competitors. According to the industry distribution chart, RAMM Pharma ranks #609 out of 950 companies in the Drug Manufacturers industry, placing it in the top 64.1%.
Is RAMM Pharma's Receivables Turnover too high?
RAMM Pharma's current Receivables Turnover is 1.96. The Drug Manufacturers industry median Receivables Turnover is 5.07. RAMM Pharma's value of 1.96 is 61.3% below this industry median. Based on the distribution chart, RAMM Pharma ranks #609 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does RAMM Pharma's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #609 out of 950 companies for Receivables Turnover. This places RAMM Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. RAMM Pharma's value of 1.96 is 61.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current Receivables Turnover of 1.96 is 61.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Receivables Turnover is 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Receivables Turnover is 1.96 and 61.3% below the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Receivables Turnover is 1.96 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 
